Stocks
Biogen Financial Statements (BIIB) |
||||||||||
| Biogensmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 06.02.2020 | 03.02.2021 | 03.02.2022 | 15.02.2023 | 31.12.2023 | 24.04.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 14 378 | 13 445 | 10 982 | 10 173 | 9 836 | 9 573 | |||
| Operating Income, bln rub | 7 043 | 4 550 | 2 841 | 2 320 | 1 297 | 1 352 | ||||
| EBITDA, bln rub | ? | 7 519 | 4 807 | 3 657 | 2 686 | 2 599 | 2 397 | |||
| Net profit, bln rub | ? | 5 889 | 4 001 | 1 556 | 3 047 | 1 161 | 1 167 | |||
| OCF, bln rub | ? | 7 079 | 4 230 | 3 640 | 1 384 | 1 547 | 1 645 | |||
| CAPEX, bln rub | ? | 669.5 | 551.8 | 294.9 | 243.2 | 311.4 | 360.7 | |||
| FCF, bln rub | ? | 6 409 | 3 678 | 3 345 | 1 141 | 1 236 | 1 284 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 5 387 | 7 193 | 6 064 | 4 993 | 5 471 | 5 153 | ||||
| Cost of production, bln rub | 1 955 | 1 805 | 2 110 | 2 278 | 2 533 | 2 560 | ||||
| R&D, bln rub | 2 281 | 3 991 | 2 501 | 2 231 | 2 462 | 2 275 | ||||
| Interest expenses, bln rub | 187.4 | 222.5 | 253.6 | 246.6 | 246.9 | 253.6 | ||||
| Assets, bln rub | 27 234 | 24 619 | 23 877 | 24 554 | 26 845 | 26 568 | ||||
| Net Assets, bln rub | ? | 13 339 | 10 686 | 10 960 | 13 388 | 14 799 | 15 213 | |||
| Debt, bln rub | 6 368 | 7 828 | 7 604 | 6 614 | 7 338 | 6 947 | ||||
| Cash, bln rub | 4 476 | 2 610 | 3 803 | 4 893 | 1 050 | 1 074 | ||||
| Net debt, bln rub | 1 892 | 5 218 | 3 801 | 1 721 | 6 288 | 5 872 | ||||
| Ordinary share price, rub | 296.7 | 244.9 | 239.9 | 276.9 | 258.8 | 242.7 | ||||
| Number of ordinary shares, mln | 187.1 | 160.9 | 149.1 | 145.3 | 144.7 | 145.2 | ||||
| Market cap, bln rub | 55 518 | 39 398 | 35 772 | 40 236 | 37 444 | 35 246 | ||||
| EV, bln rub | ? | 57 410 | 44 616 | 39 573 | 41 958 | 43 732 | 41 118 | |||
| Book value, bln rub | 4 054 | 1 840 | 2 977 | 5 789 | 217 | 701 | ||||
| EPS, rub | ? | 31.5 | 24.9 | 10.4 | 21.0 | 8.02 | 8.03 | |||
| FCF/share, rub | 34.3 | 22.9 | 22.4 | 7.85 | 8.54 | 8.85 | ||||
| BV/share, rub | 21.7 | 11.4 | 20.0 | 39.8 | 1.50 | 4.83 | ||||
| EBITDA margin, % | ? | 52.3% | 35.8% | 33.3% | 26.4% | 26.4% | 25.0% | |||
| Net margin, % | ? | 41.0% | 29.8% | 14.2% | 29.9% | 11.8% | 12.2% | |||
| FCF yield, % | ? | 11.5% | 9.34% | 9.35% | 2.84% | 3.30% | 3.64% | |||
| ROE, % | ? | 44.1% | 37.4% | 14.2% | 22.8% | 7.85% | 7.67% | |||
| ROA, % | ? | 21.6% | 16.3% | 6.52% | 12.4% | 4.33% | 4.39% | |||
| P/E | ? | 9.43 | 9.85 | 23.0 | 13.2 | 32.2 | 30.2 | |||
| P/FCF | 8.66 | 10.7 | 10.7 | 35.3 | 30.3 | 27.4 | ||||
| P/S | ? | 3.86 | 2.93 | 3.26 | 3.96 | 3.81 | 3.68 | |||
| P/BV | ? | 13.7 | 21.4 | 12.0 | 6.95 | 172.4 | 50.3 | |||
| EV/EBITDA | ? | 7.64 | 9.28 | 10.8 | 15.6 | 16.8 | 17.2 | |||
| Debt/EBITDA | 0.25 | 1.09 | 1.04 | 0.64 | 2.42 | 2.45 | ||||
| R&D/CAPEX, % | 340.6% | 723.3% | 848.2% | 917.4% | 790.6% | 630.7% | ||||
| CAPEX/Revenue, % | 4.66% | 4.10% | 2.69% | 2.39% | 3.17% | 3.77% | ||||
| Biogen shareholders | ||||||||||
